

A young boy with glasses is sitting in a black wheelchair on a gravel path that winds through a lush green forest. Sunlight filters through the trees, creating a bright, hazy atmosphere. The boy is looking directly at the camera.

# Shire

Annual Report 2014

---

**Our journey forward**

---

CFAD Exhibit 1062  
CFAD v. NPS



At Shire we have a clear and focused strategy to become a leading global biotech delivering innovative medicines to patients with rare diseases and other specialty conditions.

To this end, we work together as one to excel across four key strategic drivers: growth, innovation, efficiency and people.

View more at  
[AR2014.shire.com](http://AR2014.shire.com)



**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

	<b>Growth</b> See page 18
	<b>Innovation</b> See page 20
	<b>Efficiency</b> See page 22
	<b>People</b> See page 24

Chairman's review	<b>02</b>
Chief Executive Officer's review	<b>04</b>
Financial highlights	<b>08</b>
Where we are	<b>09</b>
Strategy and business model	<b>10</b>
Key Performance Indicators	<b>12</b>
At a glance: In-line	<b>14</b>
At a glance: Pipeline	<b>16</b>
Strategic drivers	<b>18</b>
Responsibility	<b>26</b>
Principal risks	<b>32</b>
Year in review	<b>40</b>
Review of our business	<b>42</b>

**Governance**

Board of Directors	<b>60</b>
Corporate governance report	<b>62</b>
Directors' remuneration report	<b>74</b>
Additional statutory information	<b>102</b>
Directors' responsibilities statement	<b>106</b>

**Financial statements**

Independent auditor's report	<b>107</b>
Consolidated balance sheets	<b>110</b>
Consolidated statements of income	<b>111</b>
Consolidated statements of comprehensive income	<b>112</b>
Consolidated statements of changes in equity	<b>113</b>
Consolidated statements of cash flow	<b>115</b>
Notes to the consolidated financial statements	<b>117</b>

**Other information**

Other financial information	<b>166</b>
Shareholder information	<b>173</b>
Shire head offices	<b>174</b>
Cautionary statements	<b>175</b>
Parent company financial statements of Shire plc	<b>176</b>
Shire trademarks	<b>197</b>

**Tom Garthwaite**  
Patient with Hunter syndrome

We are committed to leading the way in treatments for rare diseases such as Hunter syndrome, with the goal of helping patients like Tom lead better lives. We take inspiration from patients like Tom, continuing to research and develop innovative treatments for diseases that are often unheard of and unrecognized, providing hope for a better tomorrow.



Susan Kilsby  
Chairman

At Shire we focus on people. Those that work for us, partner with us, invest in our strategy and, above all, those who depend on the medicines we make every day. Our purpose is to help people with life-altering conditions lead better lives. We ask the questions that are raised by rare and specialty diseases and pursue new possibilities through thoughtful and innovative science.

#### Creating exceptional value

When we do what is good, we believe good follows. Value is created not just for the patients, but for physicians, caregivers, employees, communities, payers, policymakers, and shareholders—for anyone or any institution that our global company can touch. And value, we were reminded this year, can be created—and recognized—in so many ways.



### Extraordinary results

We had an eventful year in 2014. We had unprecedented financial results as you'll see in the pages to come. We completed our acquisition of ViroPharma and successfully integrated this organization, serving new patients with the product CINRYZE®, a medicine for the inflammatory condition known as Hereditary Angioedema. At the same time, we acquired two rare diseases entities—Lumena and Fibrotech. We fortified our presence in established therapies and opened doors to new ones, including Ophthalmics. We moved into our new International Operational Headquarters in Zug, Switzerland and reinvigorated our presence in Europe, Asia and Latin America. We continued to streamline operations and to put the right people into the right jobs to complement the immediate impact of mergers and acquisitions with our focus on continuing organic growth. On behalf of adults with Binge Eating Disorder, we filed in the US for a supplemental new drug application for VYVANSE® which the Food and Drug Administration ("FDA") approved on January 30, 2015 as the first and only medication for the treatment for this disorder. And, most recently, we acquired NPS Pharma bringing two exciting rare disease therapies into our product portfolio.

We were again recognized as a constituent of the FTSE4Good Index Series, a leading responsibility investment index, and also earned the distinction from Corporate Knights in their ranking of the 2015 Global 100 Most Sustainable Corporations in the World.

We accomplished all this while responding to AbbVie as it considered the role that Shire might play within its own strategic framework. We never lost sight of the company that Shire is throughout the process.

We have a strong, independent future. And we're passionate about building it.

### Executing our strategy

Our plan moving forward is to emerge as a leading global biotech focused on rare diseases and other speciality conditions. To get there, we'll continue our investment in our four key strategic drivers: growth, innovation, efficiency, and people. Under the leadership of our Chief Executive Officer, Dr. Flemming Ornskov, we'll strengthen—and sustain—our platform through our focused approach to mergers and acquisitions, pipeline advancement, and cash management. We'll rely on the people who make Shire what it is—a diversified team representing many skills and broad experiences.

### Outstanding contributions

Our Board of Directors made significant contributions to Shire throughout 2014—going far above and beyond expectations to render opinions and weigh choices. I have the distinct pleasure of working with Board members who bring the full complement of scientific, medical, financial, organizational and commercial insights to bear on complex opportunities.

In closing, I would like to extend my gratitude to the people of Shire who remained focused on what mattered most throughout the year—our patients. The world is a healthier place, thanks to Shire. Our people are the reason.

**Susan Kilsby**  
Chairman

“  
We have a strong,  
independent future.  
And we're passionate  
about building it.  
”

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.